泌尿器科領域におけるCefodizime (THR-221) の基礎的・臨床的検討
書誌事項
- タイトル別名
-
- EXPERIMENTAL AND CLINICAL INVESTIGATION OF CEFODIZIME (THR-221) IN UROLOGY
抄録
We experimentally and clinically investigated cefodizime (THR-221), a newly developed injectable antibiotic.<BR>The serum level was studied in rabbits under dehydration and overhydration after a bolus i. v. injection of 1 g of THR-221. There was no distinct difference in serum level between dehydration and overhydration.<BR>In a clinical study, 2 g of THR-221 b.i.d. was given by i.v. drip infusion for several days to 3 patients with chronic complicated cystitis and 4 with chronic complicated cystitis + acute prostatitis. Efficacy was excellent in 1 patient, moderate in 4 and poor in 2 according to the criteria of the UT! Committee. The efficacy rate was 71.4%.<BR>Efficacy was also excellent in 1 patient each with acute uncomplicated pyelonephritis and acute prostatitis, and good in 1 with acute prostatitis+acute epididymitis according to the doctor's evaluation. No adverse reactions or objective and subjective signs occurred.<BR>A slight elevation of GPT occurred in 2 patients, but improved after withdrawal of the drug.
収録刊行物
-
- CHEMOTHERAPY
-
CHEMOTHERAPY 36 (Supplement5), 617-623, 1988
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282681261343104
-
- NII論文ID
- 130004072636
-
- ISSN
- 18845894
- 00093165
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可